canin
parvoviru
type
cpv
canin
coronaviru
ccov
consid
main
pathogen
respons
acut
gastroenter
dog
cpv
first
identifi
late
major
caus
haemorrhag
gastroenter
myocard
puppi
cpv
small
singlestrand
dna
genom
kilobas
kb
symptom
cpv
infect
vari
mild
haemorrhag
enter
fever
vomit
death
sever
case
coronavirus
singlestrand
positivesens
rna
virus
larg
genom
kb
length
enter
canin
coronaviru
typic
caus
mild
enter
dog
sever
clinic
sign
observ
young
anim
singlestrand
genom
cpv
make
viru
suscept
modif
errorpron
replic
lead
signific
dna
sequenc
variat
greater
potenti
evolut
virus
measur
defin
period
growth
cpv
serial
passag
cell
cultur
presum
cpv
origin
felin
panleukopenia
viru
via
genet
mutat
evolut
shortli
emerg
entir
replac
new
type
design
possess
abil
infect
cat
dog
mideighti
anoth
type
design
began
emerg
distinguish
singl
amino
acid
aa
substitut
asparagin
asn
aspart
acid
asp
posit
major
antigen
site
capsid
protein
novel
cpv
type
call
detect
itali
progress
replac
cpv
type
sinc
detect
throughout
part
europ
includ
spain
germani
portug
unit
kingdom
well
korea
unit
state
south
america
vietnam
distinguish
substitut
glutam
acid
glu
place
asn
asp
respect
aa
residu
protein
therefor
due
posit
aa
substitut
antigen
site
possibl
differenti
type
employ
monoclon
antibodi
altern
nucleotid
sequenc
requir
substitut
glu
aa
posit
creat
novel
mboii
restrict
site
gaaga
uniqu
therefor
distinguish
restrict
enzym
analysi
infect
report
result
clinic
symptom
similar
exhibit
dog
infect
studi
report
milder
symptom
infect
anim
report
found
evid
sever
clinic
symptom
higher
rate
mortal
even
vaccin
dog
ccov
first
discov
enteropathogen
enter
ccov
exist
two
close
relat
form
origin
form
isol
name
ccovii
new
ccov
strain
identifi
itali
design
ccovi
ccovi
ii
share
high
nucleotid
homolog
viral
genom
highli
diverg
spike
protein
gene
strain
name
accord
genet
similar
observ
ccovi
ii
felin
coronaviru
fcov
ii
respect
coronavirus
contain
larg
rna
genom
highli
suscept
frequent
mutat
result
high
error
rate
rna
polymeras
result
accumul
sever
base
substitut
per
round
replic
coronavirus
accumul
small
insert
delet
genom
promot
evolut
also
undergo
high
rate
homolog
rna
recombin
mediat
copychoic
mechan
base
sequenc
homolog
surround
recombin
site
result
mechan
coronavirus
mutat
rapidli
lead
new
genotyp
ccovi
biotyp
pantrop
ccov
host
variant
canin
respiratori
coronaviru
follow
emerg
sever
acut
respiratori
syndrom
sar
human
continu
epidemiolog
surveil
cov
reinforc
consid
potenti
agent
direct
indirect
zoonos
infect
occur
singl
ccov
strain
strain
may
present
simultan
ccov
infect
gener
low
mortal
howev
recent
character
strain
detect
itali
result
fatal
diseas
consequ
system
spread
viru
death
also
caus
synergist
effect
produc
mix
infect
occur
canin
enter
virus
mix
infect
report
ccov
canin
distemp
viru
canin
adenoviru
type
mix
infect
also
report
caliciviru
dual
infect
result
ill
usual
sever
either
viru
produc
alon
synergist
mechan
common
gastroenter
virus
rotaviru
studi
demonstr
effect
calv
coinfect
group
rotaviru
group
c
rotaviru
group
rotaviru
escherichia
coli
origin
strain
still
employ
mani
commerci
vaccin
howev
strain
entir
replac
variant
type
ccovi
ii
shortli
emerg
concern
current
vaccin
may
fail
protect
pup
variant
plan
use
current
strain
vaccin
formul
led
vaccin
licens
europ
current
canin
vaccin
use
protect
ccov
base
ccovii
howev
shown
level
crossreact
ccovi
ii
limit
recombin
ccov
report
deriv
ccovii
transmiss
gastroenter
viru
swine
tgev
relat
n
termin
domain
protein
antigen
differ
also
found
tgevlik
ccov
refer
ccov
strain
result
viral
evolut
efficaci
prophylaxi
program
place
protect
dog
ccov
challeng
may
need
assess
date
epidemiolog
inform
circul
coronavirus
parvovirus
ireland
studi
undertaken
investig
preval
virus
wide
spectrum
irish
dog
without
clinic
symptom
assess
efficaci
vaccin
program
current
place
protect
virus
total
faecal
sampl
collect
symptomat
asymptomat
dog
tabl
sampl
collect
dog
age
month
year
wide
spectrum
group
includ
irish
societi
prevent
cruelti
anim
ispca
guid
dog
associ
race
greyhound
hunt
hound
domest
dog
present
veterinari
practic
repres
major
group
canin
ireland
total
nucleic
acid
extract
sampl
standard
phenolchloroform
method
ethanol
precipit
extract
nucleic
acid
resuspend
steril
store
prior
use
sampl
screen
parvoviru
pcr
amplif
segment
carboxi
terminu
cpv
open
read
frame
use
primer
reaction
condit
describ
buonavoglia
et
al
reaction
carri
mj
research
thermocycl
gmi
inc
minnesota
usa
reaction
condit
follow
min
follow
cycl
min
min
final
extens
min
posit
neg
control
includ
reaction
sampl
subject
screen
presenc
canin
coronaviru
ccov
rtpcr
amplif
polymeras
gene
use
primer
describ
stephenson
et
al
enhanc
avian
revers
transcriptas
kit
sigmaaldrich
reaction
condit
follow
min
min
follow
cycl
min
min
min
final
extens
min
sampl
test
posit
presenc
cov
conserv
polymeras
gene
subject
rtpcr
amplif
n
gene
segment
order
specif
detect
canin
coronaviru
segment
gene
amplifi
applic
sequenc
phylogenet
analysi
use
primer
reaction
condit
describ
erl
brownli
pcr
product
run
agaros
gel
follow
ethidium
bromid
stain
visual
use
uv
light
transillumin
sampl
test
posit
gene
segment
via
pcr
amplif
subject
rflp
analysi
pcr
product
restrict
enzym
digest
pcr
amplicon
digest
five
unit
restrict
enzym
mboii
fermenta
germani
visual
agaros
gel
determin
cleavag
pattern
nucleic
acid
pcr
amplicon
purifi
use
qiaquick
pcr
purif
kit
qiagen
ltd
west
sussex
england
sequenc
use
commerci
servic
mwgbiotech
ebersberg
germani
nucleotid
sequenc
submit
genbank
databas
access
number
display
tabl
nucleotid
amino
acid
sequenc
align
perform
use
clustalw
applic
bioedit
sequenc
align
editor
preliminari
analysi
accomplish
comparison
sequenc
avail
databas
use
webbas
program
blast
http
wwwncbinlmnihgovblast
phylogenet
analysi
conduct
use
mega
program
two
phylogenet
tree
base
partial
cpv
figur
ccov
figur
gene
segment
construct
maximumparsimoni
replic
maximum
ikelihood
replic
method
respect
suppli
statist
support
bootstrap
use
ccov
refer
strain
obtain
genbank
databas
display
tabl
respect
sequenc
gene
segment
analys
virus
studi
deposit
genbank
follow
access
number
sequenc
gene
segment
analys
ccov
virus
studi
deposit
genbank
follow
access
number
follow
pcr
amplif
segment
gene
singl
band
observ
seven
sampl
tabl
well
posit
control
visual
agaros
gel
sampl
clinic
healthi
dog
use
neg
control
none
produc
amplifi
product
seven
posit
parvoviru
sampl
one
sampl
also
test
posit
presenc
ccov
total
three
sampl
tabl
test
posit
presenc
cov
polymeras
gene
subsequ
presenc
caninespecif
cov
three
sampl
confirm
success
amplif
segment
n
gene
rflp
analysi
indic
none
cpv
strain
variant
type
pcr
amplicon
digest
remain
singl
band
run
agaros
gel
sequenc
analysi
confirm
find
n
terminu
gene
amplifi
isol
use
set
three
primer
design
differenti
ccovi
ccovii
amplif
gene
ccovi
produc
band
bp
wherea
amplif
gene
ccovii
produc
band
bp
strain
character
ccovi
wherea
strain
character
ccovii
sequenc
seven
cpv
strain
reveal
three
strain
possess
aa
asn
posit
protein
therefor
strain
character
strain
possess
aa
asp
posit
therefor
character
addit
sequenc
gene
three
ccov
strain
obtain
howev
sequenc
strain
exploit
analysi
follow
align
ccovi
ii
refer
strain
pcr
type
result
confirm
twelvemonth
epidemiolog
studi
conduct
southern
ireland
octob
octob
two
hundr
fifti
sampl
collect
total
symptomat
asymptomat
dog
counti
cork
kerri
sampl
sourc
sever
veterinari
clinic
irish
guid
dog
associ
hunt
hound
race
greyhound
irish
societi
prevent
cruelti
anim
ispca
tabl
primer
use
target
gene
segment
cpv
cov
detect
perform
pcr
amplif
conserv
region
polymeras
gene
allow
detect
three
group
coronaviru
subsequ
caninespecif
cov
presenc
confirm
via
pcr
amplif
n
gene
total
sampl
seven
sampl
test
posit
presenc
cpv
three
sampl
test
posit
presenc
ccov
dual
infect
detect
one
sampl
dog
infect
cpv
ccov
may
shed
viru
clinic
symptom
ceas
addit
recov
dog
may
serv
asymptomat
carrier
shed
viru
period
import
mechan
continu
circul
persist
cpv
ccov
environ
howev
studi
virus
isol
exclus
dog
present
clinic
symptom
virus
isol
sampl
sourc
veterinari
clinic
ispca
dog
age
two
month
year
sever
vaccin
previous
sampl
sourc
symptomat
dog
seven
posit
presenc
cpv
dog
present
haemorrhag
enter
three
also
present
vomit
addit
one
dog
present
pyrexia
anoth
case
result
death
tabl
three
ccov
detect
sampl
symptomat
dog
one
present
combin
cpv
mix
infect
produc
sever
haemorrhag
gastroenter
tabl
rflp
analysi
initi
use
diagnos
infect
vitro
nucleotid
sequenc
requir
substitut
glu
aa
posit
creat
new
mboii
restrict
site
gaaga
uniqu
strain
restrict
site
detect
current
isol
subsequ
gene
segment
sequenc
order
confirm
rflp
result
determin
amino
acid
isol
contain
posit
thu
reveal
isol
three
isol
possess
aa
asn
posit
protein
therefor
characteris
isol
possess
aa
asp
posit
thu
characteris
appear
correl
cpv
type
symptom
sever
varieti
phylogenet
tree
construct
inform
howev
seen
figur
gene
low
variabl
thu
particularli
inform
phylogenet
view
typic
maximum
ident
display
gene
strain
phylogenet
tree
prepar
use
maximumparsimoni
method
prove
give
best
possibl
resolut
figur
cpv
strain
subtyp
accord
singl
amino
acid
strateg
locat
involv
chang
nucleotid
sequenc
result
compar
cpv
nucleotid
sequenc
data
cpv
subgroup
b
c
segreg
three
distinct
group
sever
nucleotid
differ
less
antigen
signific
locat
gene
must
also
taken
consider
ccov
strain
identifi
differenti
use
type
pcr
base
variabl
natur
gene
spike
protein
major
antigen
determin
cov
ccovi
ii
share
high
nucleotid
homolog
viral
genom
highli
diverg
spike
protein
gene
strain
character
ccovi
strain
character
ccovii
ccovi
first
discov
itali
sinc
report
countri
unit
kingdom
greec
portug
belgium
romania
sweden
slovenia
first
report
ccovi
ii
ireland
order
confirm
pcr
type
result
sequenc
gene
three
ccov
sampl
determin
subsequ
sequenc
analysi
confirm
ccovii
preval
ccovi
accord
publish
find
although
low
number
posit
sampl
studi
lack
statist
support
provid
snapshot
epidemiolog
ccov
ireland
use
blast
analysi
determin
ccovi
strain
display
nucleotid
sequenc
homolog
ccovi
strain
elmo
itali
ccovii
strain
display
nucleotid
homolog
ccovii
strain
insavc
nucleotid
homolog
ccovii
strain
isol
unit
kingdom
consid
singlestrand
natur
cpv
render
suscept
mutat
doublestrand
viru
mutat
rate
similar
observ
rapidli
evolv
rna
virus
imper
continu
monitor
genotyp
viru
present
popul
ensur
new
type
evolv
detect
latest
cpv
variant
type
emerg
shown
produc
pathogen
clinic
outcom
case
wherea
other
lower
sever
mortal
rate
aa
determin
type
locat
major
antigen
site
mutat
affect
type
may
seriou
implic
vaccin
efficaci
antibodi
respons
gener
pup
number
commerci
licens
vaccin
avail
ireland
given
pup
six
week
four
week
later
follow
annual
vaccin
booster
shown
vaccin
base
origin
isol
protect
variant
type
challeng
howev
plan
use
current
strain
vaccin
formul
led
base
vaccin
licens
europ
number
commerci
licens
vaccin
avail
ireland
given
pup
young
age
protect
ccovrel
enter
current
vaccin
base
ccovii
howev
shown
level
crossreact
ccovi
ii
limit
lack
crossreact
also
report
origin
ccovii
strain
design
ccoviia
recent
describ
ccovii
strain
close
relat
tgev
end
spike
gene
design
ccoviib
result
rna
recombin
insert
delet
high
suscept
frequent
mutat
coronavirus
mutat
rapidli
lead
new
genotyp
ccovi
biotyp
pantrop
ccov
host
variant
canin
respiratori
coronaviru
may
present
possibl
difficulti
regard
success
vaccin
dog
dilemma
encount
vaccin
rna
virus
influenza
viru
rotavirus
evolut
virus
well
document
play
import
role
continu
requir
assess
effici
vaccin
vaccin
updat
exampl
haemagluttinin
protein
major
antigen
determin
exhibit
rate
accumul
amino
acid
substitut
approxim
per
year
similarli
human
rotaviru
strain
detect
period
palermo
itali
display
rate
accumul
amino
acid
substitut
approxim
per
year
studi
virus
isol
vaccin
unvaccin
pup
possibl
case
vaccin
carri
matern
antibodi
interf
immun
respons
pup
time
vaccin
suspect
lack
efficaci
vaccin
base
origin
strain
new
cpv
variant
circul
suggest
previous
worldwid
cpv
outbreak
observ
regularli
vaccin
dog
result
studi
conclud
although
appear
viral
evolut
cpv
type
yet
signific
problem
canin
popul
ireland
vaccin
efficaci
may
need
reevalu
anim
healthcar
industri
possibl
new
strain
eventu
emerg
popul
result
import
dog
part
world
studi
provid
evid
cpv
ccov
caus
agent
gastroenter
southern
ireland
symptomat
dog
evid
viral
shed
asymptomat
dog
also
demonstr
dual
infect
ccov
along
cpv
signific
concern
regard
anim
health
wellb
continu
surveil
would
benefici
evalu
better
vaccin
efficaci
understand
underli
mechan
vaccin
breakthrough
implement
success
prophylact
measur
